Business

Amneal Pharmaceuticals initiated shipments of its generic version of Nasonex mometasone furoate nasal spray on April 4, 2017, the company said. According to Amneal, the mometasone furoate nasal spray is its "first pharmaceutical product in spray form"; the company also markets a generic tobramycin inhalation solution. Amneal Executive VP of Sales and … [Read more...] about Amneal Pharmaceuticals launches generic mometasone furoate nasal spray

Vectura has announced that it will receive a €5 million milestone now that Bayer AG has launched the Breelib nebulizer for Ventavis iloprost inhalation solution in Poland. Breelib is an adaptation of Vectura’s FOX handheld smart nebulizer, which Vectura acquired along with its developer, Activaero, in 2014. In addition to the initial milestone, Vectura is eligible … [Read more...] about Vectura to get milestone payment after launch of Breelib nebulizer in Poland

Therapix Biosciences has signed a licensing agreement with Yissum Research Development Company for nasal drug delivery technology that it plans to use for intranasal delivery of cannabinoids, the company said. Yissum Research Development Company is Hebrew University's technology transfer company. In 2016, Therapix announced that it had licensed an intranasal … [Read more...] about Therapix Biosciences licenses nasal drug delivery tech for delivery of cannabinoids

Sunovion has launched the Utibron Neohaler indacaterol/glycopyrrolate DPI for the treatment of COPD in the United States, the company announced. Sunovion acquired the US rights to the Utibron, Seebri, and Arcapta Neohalers from Novartis in December 2016. Utibron Neohaler, which is marketed as Ultibro Breezhaler outside of the US, was approved by the FDA in … [Read more...] about Sunovion launches Utibron Neohaler in US

Judge Richard G. Andrews of the US District Court, District of Delaware, has found that Lannett has infringed on the US patents 6,750,237 and 7,220,767 related to Zomig zolmitriptan nasal spray, Impax Laboratories has announced. In 2014, Impax filed suit against Lannett after Lannett filed an ANDA for a generic version of Zomig nasal spray. In 2012, Impax … [Read more...] about Lannett found to have infringed on patents related to Zomig nasal spray

According to PARI Pharma, the company has licensed a formulation of liposomal cyclosporine A for the treatment of bronchiolitis obliterans syndrome (BOS) to Breath Therapeutics. Breath Therapeutics, a spin off of PARI, recently announced that it has raised €43.5 million in Series A Financing, which it will use for Phase 3 trials of the product, regulatory … [Read more...] about PARI Pharma licences inhaled therapy for bronchiolitis obliterans syndrome to Breath Therapeutics

AstraZeneca has announced an agreement with Circassia Pharmaceuticals for development and commercialization of the Tudorza and Duaklir dry powder inhalers in the US. AstraZeneca will receive $50 million in Circassia ordinary shares and $100 million on approval of Duaklir in the US or June 30, 2019, whichever comes first. Circassia will have the option to acquire … [Read more...] about Circassia acquires rights to Tudorza and Duaklir DPIs in the US